CN104095812A - 含阿维菌素类药物可乳化油质注射剂的制备方法 - Google Patents
含阿维菌素类药物可乳化油质注射剂的制备方法 Download PDFInfo
- Publication number
- CN104095812A CN104095812A CN201410366904.6A CN201410366904A CN104095812A CN 104095812 A CN104095812 A CN 104095812A CN 201410366904 A CN201410366904 A CN 201410366904A CN 104095812 A CN104095812 A CN 104095812A
- Authority
- CN
- China
- Prior art keywords
- preparation
- injection
- oil
- liter
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 77
- 238000002347 injection Methods 0.000 title claims abstract description 51
- 239000007924 injection Substances 0.000 title claims abstract description 51
- 239000005660 Abamectin Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 155
- 229940079593 drug Drugs 0.000 title abstract description 36
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 title abstract description 8
- 229950008167 abamectin Drugs 0.000 title abstract description 8
- 239000003921 oil Substances 0.000 claims abstract description 43
- 239000004359 castor oil Substances 0.000 claims abstract description 7
- 235000019438 castor oil Nutrition 0.000 claims abstract description 7
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 7
- 235000019198 oils Nutrition 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 32
- 239000004190 Avilamycin Substances 0.000 claims description 24
- 229960005185 avilamycin Drugs 0.000 claims description 24
- 229930192734 Avilamycin Natural products 0.000 claims description 23
- XIRGHRXBGGPPKY-OTPQUNEMSA-N [(2r,3s,4r,6s)-6-[(2'r,3's,3ar,4r,4'r,6s,7ar)-6-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4s,5s,6s)-6-[(2r,3as,3'ar,6'r,7r,7's,7ar,7'ar)-7'-acetyl-7'-hydroxy-6'-methyl-7-(2-methylpropanoyloxy)spiro[4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-2,4'-6,7a-dihydro-3ah- Chemical compound O([C@H]1[C@H](O)C[C@@H](O[C@@H]1C)O[C@H]1[C@H](O)CC2(O[C@]3(C)C[C@@H](O[C@H](C)[C@H]3O2)O[C@H]2[C@@H](OC)[C@@H](C)O[C@H]([C@@H]2O)O[C@H]2[C@H](O)[C@H](OC)[C@H](OC3[C@@H]([C@@H]4O[C@]5(O[C@H]4CO3)[C@@H]3OCO[C@H]3[C@@](O)([C@@H](C)O5)C(C)=O)OC(=O)C(C)C)O[C@@H]2COC)O[C@@H]1C)C(=O)C1=C(C)C(Cl)=C(O)C(Cl)=C1OC XIRGHRXBGGPPKY-OTPQUNEMSA-N 0.000 claims description 23
- 235000019379 avilamycin Nutrition 0.000 claims description 23
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 claims description 18
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 15
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000003963 antioxidant agent Substances 0.000 claims description 14
- 230000003078 antioxidant effect Effects 0.000 claims description 14
- 229960002418 ivermectin Drugs 0.000 claims description 14
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 13
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 11
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 11
- 229940093471 ethyl oleate Drugs 0.000 claims description 11
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 claims description 10
- 229960002903 benzyl benzoate Drugs 0.000 claims description 10
- 229940083466 soybean lecithin Drugs 0.000 claims description 8
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims description 6
- 229960002346 eprinomectin Drugs 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- -1 doractin Chemical compound 0.000 claims description 5
- 239000000473 propyl gallate Substances 0.000 claims description 5
- 229940075579 propyl gallate Drugs 0.000 claims description 5
- 235000010388 propyl gallate Nutrition 0.000 claims description 5
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 claims description 4
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 claims description 3
- 229940099245 milbemycin oxime Drugs 0.000 claims description 3
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims description 3
- 229960004816 moxidectin Drugs 0.000 claims description 3
- QSHVAZMOLNGWSY-UHFFFAOYSA-N 3-butyl-4-methoxyphenol Chemical group CCCCC1=CC(O)=CC=C1OC QSHVAZMOLNGWSY-UHFFFAOYSA-N 0.000 claims description 2
- 229940090044 injection Drugs 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 1
- 229940074928 isopropyl myristate Drugs 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 239000000839 emulsion Substances 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 9
- 210000001124 body fluid Anatomy 0.000 abstract description 5
- 239000010839 body fluid Substances 0.000 abstract description 5
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 abstract description 4
- 229920001993 poloxamer 188 Polymers 0.000 abstract description 4
- 229940044519 poloxamer 188 Drugs 0.000 abstract description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000003096 antiparasitic agent Substances 0.000 abstract 1
- 239000000787 lecithin Substances 0.000 abstract 1
- 229940067606 lecithin Drugs 0.000 abstract 1
- 235000010445 lecithin Nutrition 0.000 abstract 1
- 230000007774 longterm Effects 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 239000012071 phase Substances 0.000 description 16
- 230000001804 emulsifying effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 241001494479 Pecora Species 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 239000004531 microgranule Substances 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004945 emulsification Methods 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010008 shearing Methods 0.000 description 3
- 239000008347 soybean phospholipid Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000030852 Parasitic disease Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000507 anthelmentic effect Effects 0.000 description 2
- 230000002141 anti-parasite Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- AZSNMRSAGSSBNP-XPNPUAGNSA-N 22,23-dihydroavermectin B1a Chemical compound C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 AZSNMRSAGSSBNP-XPNPUAGNSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000005645 nematicide Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000005381 potential energy Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
制剂编号 | 阿维菌素(g) | P188(g) | HCO(g) | 大豆磷脂(g) |
制剂1 | 4 | 5 | 0.3 | 0.4 |
制剂2 | 4 | 4 | 0.6 | 0.8 |
制剂3 | 4 | 3 | 0.9 | 0.4 |
制剂4 | 4 | 9 | 0.3 | 0.4 |
制剂5 | 4 | 8 | 0.6 | 0.8 |
制剂6 | 4 | 7 | 0.9 | 1.1 |
制剂7 | 4 | 12 | 0.6 | 0.8 |
制剂8 | 4 | 3 | 0.9 | 1.1 |
制剂9 | 4 | 3 | - | - |
制剂10 | 4 | 9 | - | - |
对比制剂1 | 4 | - | 0.9 | 0.4 |
对比制剂2 | 4 | - | - | - |
制剂编号 | 伊维菌素(g) | P188(g) | HCO(g) | 大豆磷脂(g) | 苯甲酸苄酯(ml) |
制剂11 | 3 | 7 | 0.8 | 0.4 | 35 |
制剂12 | 4.5 | 5 | 0.8 | 0.4 | 50 |
制剂13 | 6 | 3 | 0.8 | 0.4 | 65 |
制剂14 | 3 | 7 | 0.8 | - | 35 |
制剂15 | 4.5 | 5 | 0.8 | - | 50 |
制剂16 | 6 | 3 | 0.8 | - | 65 |
制剂17 | 3 | 3 | - | - | 65 |
制剂18 | 4.5 | 5 | - | - | 65 |
制剂19 | 6 | 7 | - | - | 65 |
成份 | 制剂26 | 制剂27 | 制剂28 | 制剂29 | 制剂30 | 制剂31 |
EPM(g) | 4 | 6 | 8 | 6 | 6 | 8 |
P188(g) | 3 | 5 | 7 | 3 | 5 | 7 |
HCO(g) | 0.4 | 0.6 | 0.8 | 0.6 | 0.6 | - |
大豆磷脂(g) | 0.6 | 0.8 | 1.0 | - | - | - |
抗氧剂(g) | 0.035 | 0.035 | 0.035 | 0.035 | 0.035 | 0.035 |
油酸乙酯(ml) | 至100 | 至100 | 至100 | 至100 | 至100 | 至100 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410366904.6A CN104095812B (zh) | 2014-07-30 | 2014-07-30 | 含阿维菌素类药物可乳化油质注射剂的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410366904.6A CN104095812B (zh) | 2014-07-30 | 2014-07-30 | 含阿维菌素类药物可乳化油质注射剂的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104095812A true CN104095812A (zh) | 2014-10-15 |
CN104095812B CN104095812B (zh) | 2017-09-19 |
Family
ID=51664610
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410366904.6A Active CN104095812B (zh) | 2014-07-30 | 2014-07-30 | 含阿维菌素类药物可乳化油质注射剂的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104095812B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104689324A (zh) * | 2014-07-30 | 2015-06-10 | 王玉万 | 含亲水性治疗药物可乳化油质注射剂的制备方法 |
CN108992403A (zh) * | 2018-08-31 | 2018-12-14 | 田红卫 | 一种长效缓释伊维菌素注射液及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1461640A (zh) * | 2002-05-31 | 2003-12-17 | 王玉万 | 含抗寄生虫药物的缓释注射剂 |
CN103720652A (zh) * | 2014-01-07 | 2014-04-16 | 王玉万 | 用泊洛沙姆和油性介质制备含阿维菌素类药物注射剂 |
-
2014
- 2014-07-30 CN CN201410366904.6A patent/CN104095812B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1461640A (zh) * | 2002-05-31 | 2003-12-17 | 王玉万 | 含抗寄生虫药物的缓释注射剂 |
CN103720652A (zh) * | 2014-01-07 | 2014-04-16 | 王玉万 | 用泊洛沙姆和油性介质制备含阿维菌素类药物注射剂 |
Non-Patent Citations (1)
Title |
---|
周巧云等: "泊洛沙姆为载体的疏水性药物新剂型研究进展", 《中国现代应用药学》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104689324A (zh) * | 2014-07-30 | 2015-06-10 | 王玉万 | 含亲水性治疗药物可乳化油质注射剂的制备方法 |
CN108992403A (zh) * | 2018-08-31 | 2018-12-14 | 田红卫 | 一种长效缓释伊维菌素注射液及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104095812B (zh) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6266051B2 (ja) | 可逆的な連続相及び分散相を有するナノエマルション | |
CN101019833B (zh) | 一种用作药物载体的药用油包油型非水微乳及其药物制剂 | |
CN110035774A (zh) | 大麻素的可稀释制剂及其制备方法 | |
CN1500524A (zh) | 用于抗炎化合物局部释放的载体 | |
EP2948134B1 (en) | Compositions for transdermal delivery of mtor inhibitors | |
US10166187B2 (en) | Curcumin solid lipid particles and methods for their preparation and use | |
CN101511356A (zh) | 含有木脂素类化合物的o/w/o型乳液及含有该乳液的组合物 | |
US20030180350A1 (en) | Combination compositions | |
CN102048688A (zh) | 以胆固醇复合物为中间载体的紫杉醇亚微乳 | |
CN114796110A (zh) | 一种不含乙醇的难溶性药物浓缩液以及由其制备的胶束溶液 | |
CN101006997B (zh) | 复方紫杉醇及衍生物多西他赛脂肪乳剂和制备方法 | |
CN103405385A (zh) | 一种替莫唑胺静脉注射脂肪乳及其制备方法 | |
CN101623255B (zh) | 一种青蒿琥酯纳米乳药物组合物及其制备方法 | |
CN1985851A (zh) | 含有蟾酥提取物的脂质微球注射液及其制备方法 | |
CN104095812A (zh) | 含阿维菌素类药物可乳化油质注射剂的制备方法 | |
CN101147727A (zh) | 莪术醇亚微乳及其制备方法和制剂 | |
CN104095815B (zh) | 泰拉霉素可乳化注射剂的制备方法 | |
CN100515389C (zh) | 一种适用于难溶性药物的药用乳剂及其制备方法 | |
US20170232026A1 (en) | Pharmaceutical composition in ivermectin emulgel for veterinary use as a promoter system and bio-adhesive in antiparasitic treatment, and method for the production thereof | |
CN104083324B (zh) | 一种利福昔明的兽用悬乳剂及其制备方法和应用 | |
CN101491550B (zh) | 一种红曲提取物与辅酶q10复方制剂的制备方法 | |
CN103550150B (zh) | 改进的含二甲基硅油的注射剂 | |
CN102552137A (zh) | 雷公藤内酯醇脂肪乳注射剂及其制备方法 | |
CN101322688A (zh) | 供静脉用氟马西尼的水包油乳剂及制备方法 | |
CN104398478A (zh) | 兽用药物的复乳型载体及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Effective date: 20150112 Owner name: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YOU XIHUO Effective date: 20150112 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20150112 Address after: 102206 Beijing city Changping District Baishan Town East Village profile West Industrial Zone No. 535 Pro Applicant after: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. Address before: 102206 Beijing city Changping District Baishan Town East Village profile West Industrial Zone No. 535 Pro Applicant before: You Xihuo Applicant before: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 102209 C2034 2, 16 building, No. 37 Chao Yuan Road, Changping District science and Technology Park, Beijing. Patentee after: Beijing Zhongnonghuawei pharmaceutical Limited by Share Ltd Address before: 102206 535 Shanghao Village West Industrial Area, Baishan Town, Changping District, Beijing. Patentee before: BEIJING AGRICHINA PHARMACEUTICAL CO., LTD. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method for emulsifiable oily injection containing abamectin drugs Effective date of registration: 20180910 Granted publication date: 20170919 Pledgee: Huaxia Bank Beijing branch Wanliu Limited by Share Ltd Pledgor: Beijing Zhongnonghuawei pharmaceutical Limited by Share Ltd Registration number: 2018990000795 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20191122 Granted publication date: 20170919 Pledgee: Huaxia Bank Beijing branch Wanliu Limited by Share Ltd Pledgor: Beijing Zhongnonghuawei pharmaceutical Limited by Share Ltd Registration number: 2018990000795 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method for emulsifiable oily injection containing abamectin drugs Effective date of registration: 20191128 Granted publication date: 20170919 Pledgee: Huaxia Bank Beijing branch Wanliu Limited by Share Ltd Pledgor: Beijing Zhongnonghuawei pharmaceutical Limited by Share Ltd Registration number: Y2019990000606 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 102209 C2034 2, 16 building, No. 37 Chao Yuan Road, Changping District science and Technology Park, Beijing. Patentee after: Zhongnonghuawei Pharmaceutical Co., Ltd Address before: 102209 C2034 2, 16 building, No. 37 Chao Yuan Road, Changping District science and Technology Park, Beijing. Patentee before: Beijing Zhongnong Huawei Pharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210531 Granted publication date: 20170919 Pledgee: Huaxia Bank Beijing branch Wanliu Limited by Share Ltd. Pledgor: Beijing Zhongnong Huawei Pharmaceutical Co.,Ltd. Registration number: Y2019990000606 |